Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

Scientists suggest that targeting a key protein outside of the brain could help ... Precision Medicine Could Be Possible in the Fight Against Antibiotic Resistance Apr. 3, 2025 — Certain ...

The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

Experts discuss how cancer treatment and survivorship can be made more equitable and affordable through advocacy, outreach, and effective communication tools. Beyond Cancer: Caring for Young ...

For graduating medical students across the country, Friday, March 21 was Match Day. The CMU College of Medicine Class of 2025 gathered to celebrate with their families, friends, faculty and staff ...

(RTTNews) - Clearmind Medicine Inc.(CMND), Tuesday announced the initiation of its Phase I/IIa clinical trial to investigate the safety, tolerability, and pharmacokinetics of its innovative drug ...

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech ...

The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...

The UAB Department of Medicine is an integral part of one of the nation's largest health systems. Nationally known for our compassionate care, cutting-edge research, and comprehensive training ...